-
Research
-
Get Involved
-
About MRA
-
Partners
-
What's New
July 12, 2017, marked a historic day for medicine and for the US Food and Drug Administration (FDA) when an expert advisory committee to the FDA unanimously endorsed the first ever genetically engineered, cell-based therapy for use in patients.
Read More ➤
While 2014 and 2015 offered a whirlwind of good news related to new melanoma treatments from immune to targeted therapy, since then, it’s been a bit quieter in melanoma. Although, there has been exceptional news in regard to other cancers. Why is that, and what are the latest breakthroughs?
Read More ➤
With the launch of summer comes conventional discussion around ranking sunscreens, and chatter between the experts to parse what should be considered in choosing the most effective among them. It’s also a key conversation among parents heading into the season with an eye on protecting their children from sun exposure.
Read More ➤
The Melanoma Research Alliance (MRA) and the American Cancer Society (ACS) are partnering to fund much-needed research aimed at decreasing, rare but serious, and at times even life-threatening, side effects associated with checkpoint inhibitors in hopes of increasing further cancer immunotherapy benefit to patients.
Read More ➤
Following 22 years of fundraising and management experience in healthcare, higher education and NPOs, Joan Russo is joining the Melanoma Research Alliance (MRA) as Chief Development Officer.
Read More ➤